The board of the state-owned company UAB “Valstybės investicinis kapitalas” (legal entity code 305611945) has decided to approve the increase in the authorized capital of UAB “EPSO-G Invest”. UAB “Valstybinis investicinis kapitalas” has owned 49 percent of the shares of UAB “EPSO-G Invest”. UAB “EPSO-G Invest” legal entity code 306949519 authorized capital is increased by EUR 3,360,600 from EUR 7,405,600 to EUR 10,765,600, by issuing 3 360 000 ordinary registered intangible shares of UAB “EPSO-G Invest” with a nominal value of EUR 1.

The issue price of one newly issued share is EUR 10. The total issue price of the newly issued share issue of EPSO-G Invest is equal to EUR 33,600,000. The difference between the issue price and the nominal value of the newly issued EPSO-G Invest shares, amounting to EUR 30,240,000, shall be credited to the share premium.

The authorized capital of UAB EPSO-G Invest is increased by issuing and distributing 3,360,000 new ordinary registered shares to the shareholders according to the following procedure and portions:

  1. EPSO-G: 1,713,600 shares, with a total issue price of EUR 17,136,000, consisting of the total nominal value of these shares equal to EUR 1,713,600 and a share premium of EUR 15,422,400;
  2. UAB Valstybės investicinis kapitalas: 1,646,400 shares, with a total issue price of EUR 16,464,000, consisting of the total nominal value of these shares equal to EUR 1,646,400 and a share premium of EUR 14,817,600.

Contact person:

Vaidas Daktariunas
Valstybės investicinis kapitalas UAB, Chief Executive Officer
Phone: +370 656 03356
E-mail: info@vika.lt

Press contact:
Sereydana Oum
Tel.: + 33 6 61 42 03 59
E-mail: sereydana.oum@capgemini.com

Businesses accelerate their climate adaptation investments
yet just 15% have fully quantified the financial impact of climate-related risks

  • Nearly 7 in 10 executives are prioritizing climate adaptation to boost business resilience
  • Share of organizations falling behind on net zero goals up to 11% in 2026, from 1% in 2025
  • Access to critical resources is becoming a stronger driver of sustainability decisions than emissions-reduction targets for more than 7 in 10 organizations

Paris, September 16, 2026 – Climate disruption, water stress, resource constraints, and geopolitical volatility are increasing pressure on business operations, supply chains and growth. According to the fifth edition of the Capgemini Research Institute’s A World in Balance: The resilience reset report, organizations are responding by placing greater emphasis on climate adaptation and business resilience1. In addition, nearly two-thirds of organizations say they use AI to advance their sustainability agenda. However, the research also reveals a widening gap between ambition and delivery, as more organizations fall behind on net zero commitments and struggle to measure climate- and AI-related impacts.

Sustainability strategies increasingly focus on resilience, business continuity, and access to critical resources
Nearly nine in 10 organizations report that climate-related events have disrupted their supply chains. In response, 68% of executives say their organization actively prioritizes climate adaptation, up from 56% in 2025. The way business leaders perceive sustainability is evolving, stretching beyond reporting and compliance and increasingly being seen through the lens of measurable business outcomes, resilience, continuity, and access to critical resources. Nearly two-thirds of executives identify energy- and critical-resource security as a key driver of sustainability investment. More than seven in 10 say that securing access to critical resources – including energy, water, and materials – now has greater influence on sustainability decision-making than emissions-reduction targets.

This transition is also reshaping organizations’ strategic priorities, with more than three-quarters of executives saying their organization is accelerating efforts to integrate energy and resource resilience into business and sustainability strategies. Alongside energy security, water-related risks are a growing concern – 61% of executives believe water scarcity will present a greater constraint on business growth than energy availability over the next five years.

While awareness of these risks is growing, operational readiness remains inconsistent. Just 15% of organizations have fully quantified the financial impact of climate-related disruptions, with just over one in four executives say their organization has assessed climate risks across its extended value chain or deployed climate-risk analytics tools or platforms. Nevertheless, there are signs that adaptation capabilities are maturing – the share of executives who say their organization is underprepared for climate impacts has fallen from 54% in 2025 to 44% in 2026.

“Climate change disruptions have become our new normal, and yet there is still a wide gap between business leaders’ awareness of the risks and actual implementation. In order to protect their supply chains, operations, infrastructure, and access to essential energy, water, and materials, they can no longer defer climate action,” said Cyril Garcia, Global head of Sustainability services and Corporate Responsibility, and Member of the Group Executive Board at Capgemini. “It is encouraging to see organizations prioritize adaptation and resilience for sustainable growth. But as climate and political risks evolve, organizations must continue to embed sustainability into their core business strategy and day-to-day operations.”

Sustainability investments continue to demonstrate a positive ROI
Nearly seven in 10 organizations say their sustainability initiatives have generated a net-positive return on investment. Almost two-thirds of executives (64%) say sustainability investments have boosted sales, up from 47% in 2025, and 74% acknowledge that sustainable practices have enhanced their brand equity.

Looking ahead, 83% say their organization will increase climate adaptation spending over the next 12-18 months, reflecting a trend that is already visible today: organizations spent 1.04% of revenue on sustainability initiatives last year, exceeding the 0.8% they initially allocated. This investment is also helping organizations manage business disruption, as nearly two-thirds of executives from manufacturing or asset-intensive sectors say these investments have improved operational efficiency under supply constraints, while slightly over half say they have enhanced their ability to anticipate and respond to operational and supply-chain disruptions.

Businesses struggle to follow through with their net zero commitments
While most organizations have sustainability goals, the research suggests that implementation remains challenging. In 2026, 84% of organizations say they have set science-based targets, up three points since 2025. Yet only 42% say they are on track to meet their 2030 or interim targets. The execution gap is particularly visible in net zero programs. The number of organizations falling behind on their net zero goals has increased more than tenfold since last year. Moreover, 29% say they have postponed their net zero objectives, compared with just 8% last year.

Nearly two-thirds of organizations acknowledge that aligning sustainability efforts with science-based targets is challenging. Data availability, measurement, and value-chain visibility remain challenging. The proportion of organizations able to measure and collect data across all Scope 3 emissions has fallen to 34%, from 54% in 2025, underscoring the difficulty of tracking and managing emissions beyond direct operations.

AI supports sustainability initiatives, but environmental impact is hard to measure
AI is also increasingly considered as a tool to help turn sustainability ambition into action. Nearly two-thirds of organizations say they use AI to advance their sustainability agenda, and more than a third use or plan to use agentic AI for sustainability initiatives. At the same time, the environmental implications of AI are increasingly being recognized at senior levels. Seven in 10 organizations say AI’s sustainability implications are discussed in the boardroom.

However, oversight and disclosure of the technology remain limited. Nearly half of executives say AI has significantly increased greenhouse gas emissions. Yet concern about AI’s environmental impact appears to be outpacing organizations’ ability to measure it: just over a third of executives say their organization measures the energy consumption of AI systems and workloads, and the associated carbon footprint.

To access the full report: https://www.capgemini.com/insights/research-library/sustainability-trends-2026/

Methodology of the report
The Capgemini Research Institute surveyed 2,100 executives employed at 701 organizations, each with more than $1 billion in annual revenue, across 13 countries in North America, Europe, and Asia-Pacific and in 12 industries and sectors. Respondents represented industries and sectors covered across: aerospace and defense, agriculture and forestry, automotive, consumer products, energy, financial services, healthcare and life sciences, industrial manufacturing, retail, telecom, utilities, and the public sector/government. The survey took place in June and July 2026. The research also includes a global survey of 6,500 consumers and interviews with 15 executives at leading organizations.

About Capgemini
Capgemini is the business transformation partner for enterprises in the age of AI. We help organizations imagine and build an intelligent, sustainable future, combining AI, technology and human ingenuity to transform how they operate, innovate and grow. With unique end-to-end capabilities spanning strategy, technology, engineering and intelligent operations, we bring together deep industry expertise and market-leading capabilities in AI, cloud and data to turn ambition into measurable business outcomes at scale. Supported by a robust ecosystem of partners and nearly 60 years of expertise, Capgemini is a responsible and diverse global organization of over 410,000 team members in more than 50 countries. The Group reported 2025 revenues of €22.5 billion.

Make it real | www.capgemini.com

About the Capgemini Research Institute
The Capgemini Research Institute is Capgemini’s in-house think-tank on all things digital. The Institute publishes research on the impact of digital technologies on large traditional businesses. The team draws on the worldwide network of Capgemini experts and works closely with academic and technology partners. The Institute has dedicated research centers in India, Singapore, the United Kingdom and the United States. It was ranked #1 in the world for the quality of its research by independent analysts for six consecutive times – an industry first.

Visit us at https://www.capgemini.com/researchinstitute/


1 Resilience refers here to an organization’s ability to anticipate, adapt to, and withstand disruptions across its operations, supply chains, resources, and markets.

Attachment

Kalmar and ICTSI continue collaboration with hybrid straddle carrier order

Kalmar has concluded an agreement with International Container Terminal Services, Inc. (ICTSI) to supply a total of 12 Kalmar hybrid straddle carriers.
Kalmar has concluded an agreement with International Container Terminal Services, Inc. (ICTSI) to supply a total of 12 Kalmar hybrid straddle carriers.

KALMAR CORPORATION, PRESS RELEASE, 16 SEPTEMBER 2026 AT 9.00 (EEST)

Kalmar and ICTSI continue collaboration with hybrid straddle carrier order for new South Luzon Container Terminal

Kalmar has concluded an agreement with International Container Terminal Services, Inc. (ICTSI) to supply a total of 12 Kalmar hybrid straddle carriers. The machines will be deployed at the South Luzon Container Terminal (SLCT), located within Bauan International Port in Batangas, the Philippines. The significant order, which also includes MyKalmar INSIGHT coverage for all machines, was booked in Kalmar’s Q3 2026 order intake, with delivery of all machines scheduled to be completed during Q3 2027.

ICTSI is one of the largest and most successful container terminal operators in the Philippines and a world leader in providing container handling, storage and related services to shipping lines and cargo owners. 

The South Luzon Container Terminal (SLCT) is located approximately 110 kilometers south of Manila, within the Bauan International Port in Batangas, and will support industrial and manufacturing activities. Once completed, SLCT will have an 800‑metre quay, 38 hectares of yard and an annual capacity of 1.6 million TEU.

As part of the agreement, Kalmar will also supply a straddle carrier simulator. The simulator will be located at the terminal and will be used to train new operators and in the future enable existing operators to refresh their skills.

Arthur de Jonge, Senior Director Projects and Systems ICTSI: “The SLCT project represents a significant investment for our organisation and demonstrates what can be achieved through long-term collaboration and commitment. As a long-term partner, Kalmar can offer the proven technology and unparalleled service and fleet management expertise that a project of this nature demands. We are very pleased to be able to continue our collaboration.”

Daniel Ho, Vice President, GTO Key Account Management, Kalmar: “Kalmar and ICTSI have a long and distinguished history of close collaboration at a number of terminals around the world. We are proud to be able to deliver the very first Kalmar straddle carriers to a terminal in the Philippines and grateful for the trust the ICTSI have placed in our proven hybrid technology.” 

Further information for the press:

Daniel Ho, Vice President, GTO Key Account Management, Kalmar, tel.+65 9746 7375 daniel.ho@kalmarglobal.com

Annelies Nentjes, Director Marketing and Communications Horizontal Transportation, Kalmar, tel. +31 6 1323 98 46, annelies.nentjes@kalmarglobal.com  

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachment

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 16 September 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares

15 September 2026
Number of Shares purchased

39,142 Class A Shares
Highest price/lowest price paid

£14.50 / £14.32
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 38,692,560‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 38,692,560 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger
Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.
Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

TME PHARMA CEO MESSAGE

Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today publishes a message from its CEO for the shareholders.

Dear Shareholders,
As I look back on the recent period, one clear feeling dominates: remained confidence in the path we are taking. We fully understand that many of you are eager to see concrete decisions. When reaching a decisive phase, waiting can naturally feel long. However, as you know, thorough negotiations and strategic choices do not happen overnight.        
As we move through a pivotal phase for TME Pharma, I would like to share an update on our strategic approach, our financial discipline, and our commitment to long-term value creation.
Our focus remains squarely on securing an outcome that properly reflects the significant potential of our lead asset, NOX-A12.

Executive Alignment & Capital Discipline
My management philosophy across the entities I lead is rooted in absolute alignment with long-term shareholders. We strictly control overhead, and my personal compensation framework is structured to lower cash consumption and to emphasize long-term upside tied directly to company performance and share price appreciation. Furthermore, through direct personal investments and capital contributions, my priority has consistently been to protect existing shareholders from unnecessary dilution wherever possible.

Since June 2025, our disciplined cost-reduction strategy has proven essential. By streamlining our burn rate, we successfully extended our financial runway into the second quarter of 2027. Through the use of standard bond financing, we have maintained a very limited level of dilution since December 2024. This deliberate approach was executed to ensure that TME Pharma retained the independence and time needed to negotiate from a position of strength.

Capitalizing on Market Dynamics
Our capital management strategy was designed to ensure the company was well-positioned as biotech sector sentiment and deal-making dynamics improved. We are observing increasingly positive momentum in the industry, marked by renewed capital flows and strategic demand for clinical-stage assets. TME Pharma is structured to leverage these favorable market conditions for the benefit of our shareholders.

Ongoing Strategic Partnering for NOX-A12
Following our announcement on August 24, 2026, we are continuing our evaluation process. In our discussions with potential partners, our primary focus is to safeguard long-term success. This entails ensuring that the upcoming Phase 2 GLORIA trial is effectively executed under a robust regulatory strategy. In addition, we focus on securing favorable financial terms for our shareholders; a licensing agreement must generate value for shareholders throughout the process so that, in the event of a successful market launch of NOX-A12, we can ultimately benefit from a substantial percentage of peak sales capacity.        
We are working diligently to conclude this final assessment phase and look forward to updating the market as soon as a definitive decision has been reached and formal agreements are finalized.

Future additional activities        
In addition to our developments with our biotech assets, among which NOX-E36 remains a promising asset, I will continue to apply my knowledge and expertise as an investor to create value for TME Pharma shareholders in other areas as well. TME Pharma is a holding company, making it ideally suited to expand its activities and assets.        
We believe that communication with our shareholders is important, but since we only present financial reports on a semi-annual basis, we will choose, if there is enough to report, to keep you informed of developments more frequently through this channel.

Thank you for your continued support and shared vision as we execute these critical strategic milestones.

Sincerely,

Diede van den Ouden
Chief Executive Officer, TME Pharma N.V.

For more information, please contact:
TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com
www.tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.        
TME Pharma has currently 2 main assets for development:

  • NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe.
  • NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect.

The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:

  • Raising funds from alternative sources
  • Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company
  • Leveraging tax loss carry forwards

Further information can be found at: www.tmepharma.com.

About the GLORIA Study

The GLORIA (NCT04121455) ‘ready to go’-study is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain “forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.

Attachment

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer’s Disease, a Progressive Disease

TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI®” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration.

LEQEMBI Pen is an autoinjector formulation that enables administration by a care partner or patient self-administration, with two pens (totaling 500 mg) administered once weekly. With this approval, LEQEMBI treatment now offers a new option of once-weekly SC administration at home*, in addition to intravenous (IV) administration every two weeks in a hospital setting.

LEQEMBI Pen may reduce the time required for anti-amyloid therapy administration compared with IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration may reduce the burden of clinic visits for patients and their care partners and provide greater flexibility in treatment, allowing patients to make treatment choices that better fit their lifestyles, including fewer constraints on going out and traveling. The improved convenience and flexibility of treatment with LEQEMBI is expected to lower barriers to initiating and continuing treatment with LEQEMBI. Furthermore, LEQEMBI Pen also has the potential to reduce healthcare resources associated with IV dosing, such as nurse monitoring, as well as maintaining infusion capacity. These features are expected to contribute to further streamlining the overall Alzheimer’s disease (AD) treatment pathway. For amyloid-related imaging abnormalities (ARIA) monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation.

AD is a progressive, relentless disease with Aβ and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3 Only LEQEMBI fights AD in two ways – targeting both protofibrils and amyloid plaque.

This marks the third country globally to approve LEQEMBI SC formulation. This approval is based on the integrated results of data and associated modeling and simulation from the 18-month core study of the Phase 3 Clarity AD study of LEQEMBI in patients with mild cognitive impairment (MCI) due to AD or mild AD dementia (collectively referred to as early AD), as well as multiple SC administration sub-studies in its subsequent long-term extension study (LTE). Once-weekly administration of SC formulation 500 mg demonstrated similar exposure to IV administration once every two weeks and supported the expectation that the SC formulation provides efficacy comparable to that of the IV formulation. The overall safety profile of SC administration was generally similar to that of IV administration, while systemic injection/infusion-related reactions were observed less frequently with SC administration (1.4%)** than with IV administration.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

* At-home, self-administration using LEQEMBI Pen will be possible after it is listed in the injectable drug list designated by the Minister of Health, Labour and Welfare that health insurance doctor can administer (or prescribe), following deliberation and approval by the Central Social Insurance Medical Council, in principle within 60 days after approval. In addition, the following points are stipulated to be observed when self-administering.

  • When initiating administration, treatment must be administered by a physician or under the direct supervision of a physician at a medical facility.
  • With regard to the applicability of self-administration, the appropriateness thereof shall be carefully considered, and only after providing thorough education and training, and confirming that the patient or family member/caregiver understands the risks associated with administration of this drug and how to respond to them, and that the patient or family member/caregiver is able to reliably administer it themselves, shall self-administration be implemented under the management and guidance of a physician.

** Incidence in participants newly initiated on lecanemab treatment via SC administration, based on clinical data obtained from once-weekly subcutaneous administration of lecanemab 720 mg using vial formulations.

Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 7760 619251
Emea-comms@eisai.net

Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945
Libby_Holman@Eisai.com

Biogen Inc.
Madeleine Shin 
+1-781-464-3260
public.affairs@biogen.com
INVESTOR CONTACTS  
   
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Tim Power
+ 1-781-464-2442
IR@biogen.com
   

Notes to Editors

  1. Product Outline
    1) Product name
        LEQEMBI® Pen
    2) Generic name
        Lecanemab (recombinant)
    3) Indication for use
        Slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease.
    4) Dosage and administration
        The usual dose of lecanemab (recombinant) is 500 mg injected subcutaneously once weekly.
  2. About lecanemab (generic name, brand name: LEQEMBI®)
    Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

    Lecanemab has been approved in 53 countries and regions including Japan, the U.S., China, Canada, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. In September 2023, Eisai received approval in Japan for lecanemab as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 9 countries and regions including the U.S., China, the UK, and others, and applications have been filed in 11 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing (360 mg) with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the U.S. in July 2026 and China in September 2026, and applications are under review in 2 countries.

    Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

  3. About Protofibrils 
    Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2

  4. About the Collaboration between Eisai and Biogen for AD
    Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
  5. About the Collaboration between Eisai and BioArctic for AD
    Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
  6. About Eisai Co., Ltd.
    Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

    In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

    For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

  7. About Biogen
    Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

    The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

    Biogen Safe Harbor
    This news release contains forward-looking statements, including those about the potential clinical effects of LEQEMBI (lecanemab); the potential benefits, safety and efficacy of LEQEMBI; the potential for LEQEMBI Pen to increase flexibility in treatment options and reduce use of healthcare resources and the time required for and burden of clinical visits; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer’s disease; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

    These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

    These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

    Digital Media Disclosure
    From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

  1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
  2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
  3. Hampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.

BIRMINGHAM, Ala., Sept. 16, 2026 (GLOBE NEWSWIRE) — Diversified Energy Company (NYSE:DEC; LSE:DEC) announced on May 6, 2026, a dividend in respect of the first quarter ended March 31, 2026, in the amount of 29 cents per share (the “Q1 2026 Dividend”).  The Company will pay the Q1 2026 Dividend on September 30, 2026, to those shareholders on the register on August 28, 2026. 

The Company announces that shareholders who have elected to receive their dividends in GBP sterling will receive an equivalent dividend payment of 21.567 pence per share, based on the September 10, 2026 exchange rate of GBP 0.73781 =US $1.00.

For further information, please contact:

Diversified Energy Company +1 973 856 2757
Doug Kris dkris@dgoc.com
Senior Vice President, Investor Relations & Corporate Communications www.div.energy
   
FTI Consulting dec@fticonsulting.com
U.S. & UK Financial Public Relations  

About Diversified Energy Company

Diversified is a leading publicly traded energy company focused on acquiring, operating, and optimizing cash generating energy assets. Through our unique differentiated strategy, we acquire existing, long-life assets and invest in them to improve environmental and operational performance until retiring those assets in a safe and environmentally secure manner. Recognized by ratings agencies and organizations for our sustainability leadership, this solutions-oriented, stewardship approach makes Diversified the Right Company at the Right Time to responsibly produce energy, deliver reliable free cash flow, and generate shareholder value.

ICG Enterprise Trust plc (the “Company”)

16 September 2026

Transaction in Own Shares

The Company announces that on 15 September 2026 it bought back 5,549 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1400 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,179,951
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,374,241

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Lochem, 16 September 2026

ForFarmers expands operations in Poland with acquisition of STW SA

ForFarmers, through its Polish subsidiary Tasomix, has entered into an agreement to acquire 100% of the shares in STW SA, an animal feed producer based in Sokołów Podlaski (eastern Poland). The transaction is in line with the growth strategy of ForFarmers to further strengthen their position in the Polish market, particularly in the poultry, ruminant and swine sectors. The acquisition is subject to approval by the Polish competition authority. The transaction is expected to be finalized at the beginning of 2027.

STW SA: modern feed production site
STW SA was founded in 2016 and is owned by the Leszczyński family. The company operates a modern feed production facility in Eastern Poland and is also active in feed logistics and poultry farming. Following recent investments, the annual feed production capacity has increased to approximately 270,000 tonnes. With a workforce of 76 employees, STW SA has developed substantial expertise and technical know-how in feed formulation.

Stronger position in an attractive growth market
Tasomix, which has been operating in Poland for over 35 years and has been part of ForFarmers since 2018, has been collaborating with STW SA for several years. As part of this partnership, STW SA already manufactures for Tasomix. 

“This acquisition, in which we are acquiring the production site and the product and customer portfolio, is a good addition to Tasomix’s activities in eastern Poland and creates scope for further growth. In addition, we will benefit from STW SA’s knowledge and experience and realise efficiency gains in production and logistics. This will enable us to serve our customers even better and further strengthen our position in the Polish market,” says Paweł Świerkula, Managing Director of Tasomix.

Michał Leszczyński, CEO of STW SA: “We are convinced that this acquisition lays a strong foundation for further growth and development. The combination of local commitment with the scale, knowledge and expertise of ForFarmers/Tasomix creates new opportunities for customers and employees. We look forward to working together to make this next step a success.”

Scope of the transaction
The transaction comprises the feed business with its modern production facility, excluding the feed logistics and poultry farming of the Leszczyński family.  Tasomix and  Leszczyński family intend to further strengthen their cooperation, particularly in the areas of logistics and the supply of feed to the poultry farms of the Leszczyński family.

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Note to the editor:
Media: Ilse Niehof-Duivelshof, T: +31 (0)573 28 88 00
Investors: Floor van Maaren, T +31 (0)573 28 88 00

Company profile
ForFarmers N.V. (ForFarmers) is a leading player in Europe, offering complete feed solutions for (organic) livestock farming and with annual sales of over 10 million tonnes of animal feed. With its mission statement ‘For the Future of Farming’, ForFarmers is committed to future-proof farming and making the agricultural sector even more sustainable. The company has production operations in the Netherlands (where the head office is located), Germany, Poland and the United Kingdom, and exports to various countries within and outside Europe. ForFarmers employs around 3,000 people and is listed on Euronext Amsterdam.

ForFarmers N.V., PO-Box 91, 7240 AB Lochem
T: +31 (0)573 28 88 00 – info@forfarmers.eu – www.forfarmersgroup.eu/en

FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements that include ForFarmers’ regulatory capital and liquidity positions under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements containing words such as ”intends”, ”expects”, ”takes into account”, ”aims at”, ”has the plan”, ”estimates” and words of similar purport. These statements concern or may affect future matters, such as ForFarmers’ future financial results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results and performance to differ materially from the expected future results or performance implicitly or explicitly contained in forward-looking statements. Factors that may cause, or contribute to, differences in current expectations include, but are not limited to: developments in legislation, technology, taxation, case law and regulations, fluctuations in stock prices, legal proceedings, investigations by regulators, competitive conditions, and general economic conditions. These and other factors, risks and uncertainties that may affect any forward-looking statement or the actual results of ForFarmers are discussed in the latest published annual report. The forward-looking statements contained in this document relate solely to statements as of the date of this document, and ForFarmers assumes no obligation or responsibility to update the forward-looking statements contained in this announcement, whether in connection with new information, future events or otherwise, unless ForFarmers is required by law to do so.

Company presentation

BW Offshore is presenting today at Pareto Securities’ annual Energy Conference. Please see the attached presentation.

For further information, please contact:
Ståle Andreassen, CFO, +47 91 71 86 55
IR@bwoffshore.com   www.bwoffshore.com

About BW Offshore:

BW Offshore engineers innovative floating production solutions. The Company has a fleet of FPSOs and floating wind solutions. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets worldwide. BW Offshore has around 900 employees and is publicly listed on the Oslo stock exchange.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.